[Federal Register Volume 66, Number 83 (Monday, April 30, 2001)]
[Notices]
[Pages 21407-21408]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-10579]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Identification of TRP-2 
as a New Human Tumor Antigen Recognized by Cytotoxic T Lymphocytes

AGENCY: National Institutes of Health, Public Health Service, 
DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) 
and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license to practice the inventions embodied in U.S. Patent 
Applications S/N 08/725,736, filed on October 4, 1996, and now U.S. 
Patent 5,831,016 which issued on November 3, 1998; S/N 09/161,877 (DIV 
of 08/725,736), filed on September 28, 1998, and now U.S. Patent 
6,132,980 which issued on October 17, 2000; S/N 09/162,368 (DIV of 08/
725,736), filed on September 28,

[[Page 21408]]

1998, and now U.S. Patent 6,083,703 which issued on July 4, 2000; and 
S/N 09/651,210 (DIV of 08/725,736), filed on August 30, 2000, all 
entitled ``Identification of TRP-2 as a New Human Tumor Antigen 
Recognized by Cytotoxic T Lymphocytes'; and PCT Patent Application PCT/
US97/02186 (based upon U.S. Patent Applications S/N 08/599,602 and 08/
725,736) filed on February 6, 1997, entitled ``Human Cancer Antigen of 
Tyrosinase-Related Protein 1 and 2 and Genes Encoding Same'', to 
Therion Biologics Corporation of Cambridge, Massachusetts. The patent 
rights in these inventions have been assigned to the United States of 
America.
    The prospective exclusive license territory will be worldwide and 
the field of use may be limited to recombinant poxvirus-based vaccines 
for human cancer immunotherapy, said poxviruses encoding TRP-2 or 
modifications, derivatives, or immunogenic peptides thereof, and 
vaccination protocols comprising the administration of one or more 
immunogenic TRP-2 peptides in addition to a recombinant poxvirus-based 
vaccine (for example, in a prime and boost protocol), but specifically 
excluding the use of TRP-2 peptides in any context other than a 
recombinant poxvirus-based vaccination protocol.

DATES: Only written comments and/or license applications which 
are received by the National Institutes of Health on or before June 29, 
2001 will be considered.

ADDRESSES: Requests for copies of the patents/patent 
applications, inquiries, comments and other materials relating to the 
contemplated exclusive license should be directed to: Elaine White, 
M.B.A., Technology Licensing Specialist, Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, MD. 20852-3804. Telephone: (301) 496-7056, X282; Facsimile 
(301) 402-0220; E-mail [email protected].

SUPPLEMENTARY INFORMATION: The prospective exclusive license 
will be royalty-bearing and will comply with the terms and conditions 
of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license 
may be granted unless within sixty (60) days from the date of this 
published notice, the NIH receives written evidence and argument that 
establish that the grant of the license would not be consistent with 
the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: April 23, 2001.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 01-10579 Filed 4-27-01; 8:45 am]
BILLING CODE 4140-01-P